Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE

(ABBV)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/20/2019 05/21/2019 05/22/2019 05/23/2019 05/24/2019 Date
79.82(c) 80.88(c) 81.59(c) 81.15(c) 80.06(c) Last
4 395 510 4 841 857 4 219 477 3 299 440 3 806 579 Volume
+0.45% +1.33% +0.88% -0.54% -1.34% Change
More quotes
Financials (USD)
Sales 2019 32 773 M
EBIT 2019 15 460 M
Net income 2019 10 641 M
Debt 2019 32 289 M
Yield 2019 5,30%
Sales 2020 34 637 M
EBIT 2020 16 221 M
Net income 2020 11 353 M
Debt 2020 27 401 M
Yield 2020 5,71%
P/E ratio 2019 11,00
P/E ratio 2020 9,46
EV / Sales2019 4,60x
EV / Sales2020 4,21x
Capitalization 118 B
More Financials
Company
AbbVie specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with... 
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Surperformance© ratings of AbbVie
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBVIE
05/23ABBVIE : reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCP..
AQ
05/21ABBVIE : Launches ORILISSA™ (elagolix) 200 mg BID Dose for the Treatment o..
AQ
05/20ABBVIE : Provides Update on Depatuxizumab Mafodotin, an Investigational Medicine..
AQ
05/20ABBVIE : Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigatio..
AQ
05/17ABBVIE : halts enrollment after brain cancer trial misses goal, shares fall
RE
05/17ABBVIE : Glioblastoma Drug Misses Primary Endpoint
DJ
05/17ABBVIE : Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigatio..
PR
05/16ABBVIE : Announces US FDA Approval of VENCLEXTA as a Chemotherapy-Free Combinati..
AQ
05/15Genentech Says FDA Approves Venclexta Plus Gazyva for Chronic Lymphocytic Leu..
DJ
05/15GLOBAL MARKETS LIVE : Barclays, Ford, Facebook, Walmart…
More news
Analyst Recommendations on ABBVIE
More recommendations
Sector news : Pharmaceuticals - NEC
05/24NOVARTIS : At $2 Million, New Novartis Drug Is Priciest Ever
DJ
05/24NOVARTIS : Correction to Novartis Article
DJ
05/24NOVARTIS : FDA Approves Novartis' Piqray for Breast Cancer
DJ
05/24NOVARTIS' : Zolgensma Approved for Sale in U.S. to Treat SMA in Infants at $2.12..
DJ
05/24SAMSUNG ELECTRONICS : South Korea orders further arrests at Samsung Electronics ..
RE
More sector news : Pharmaceuticals - NEC
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Average target price 90,5 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Senior Vice President-Operations
Robert A. Michael Chief Financial Officer & Senior Vice President
Carlos Alban Vice Chairman & Chief Commercial Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE-13.16%118 355
JOHNSON & JOHNSON8.32%368 655
PFIZER-3.96%233 239
ROCHE HOLDING LTD.11.42%233 096
NOVARTIS17.44%219 832
MERCK AND COMPANY6.23%208 984